Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of SB5 Pen vs PFS in Healthy Subjects
NCT02326233Phase 1Completed
- Sponsor
- Samsung Bioepis
- Start
- Jun 2015
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Samsung Bioepis. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity at 1344 hours, Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration at 1344 hours and 1 more. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02326233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326233.